Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Biohaven Therapeutics Ltd.
- Study ID
- NCT06419608
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- BHV-7000 — DRUGBHV-7000 75 mg taken once daily for 6 weeks
- Placebo — DRUGMatching placebo taken once daily for 6 weeks
Study Details
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Key Dates
- Start date
- May 28, 2024
- Status verified
- Jan 2026
- Primary completion
- Nov 7, 2025
- Completion
- Nov 7, 2025
Study Design
- Enrollment
- 336 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: BHV-7000
- Placebo Comparator: Placebo
Primary Outcome Measure
Change in Montgomery- Åsberg Depression Rating Scale (MADRS) total score from baseline to week 6 [ Time Frame: Baseline to Week 6 ]
Locations (62)
Find similar trials in Phoenix, AZ
By condition
By specialty
Related Studies
- Study of Neuro-Cognitive Correlates of Pediatric Anxiety DisordersPHASE2 · Recruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderPHASE1 · Recruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- DBS for DepressionRecruiting · Baylor College of Medicine · Dallas, Texas
- Nitrous Oxide- Suicidal IdeationPHASE1 · Enrolling By Invitation · Washington University School of Medicine · St Louis, Missouri